Spirulina and Gut Microbiome / Short-Chain Fatty Acids.

Spirulina Polysaccharides as Prebiotic Substrates

Spirulina contains ~15–25% carbohydrate by dry weight, primarily as sulphated polysaccharides (spirulan; calcium spirulan; MW ~70–170 kDa; rhamnose/mannose/galactose/xylose backbone with sulphate esters and iduronic acid) and glycogen-like polymers. Spirulan is resistant to mammalian digestive enzymes (no mammalian sulphatase; no α-galactosidase for rhamnan degradation), reaching the colon intact as a prebiotic substrate. Colonic Bacteroidetes (Bacteroides fragilis; Prevotella; Faecalibacterium prausnitzii) and Firmicutes (Roseburia intestinalis; Eubacterium rectale; Clostridium butyricum) ferment these polysaccharides via glycoside hydrolases (GH97, GH29 α-L-rhamnosidases; GH42 β-galactosidases; sulphatases) generating acetate, propionate, and butyrate (SCFA). Spirulina peptides (phycocyanin fragments post-GI digestion) may also reach the colon and modulate microbial composition.

Butyrate: HDAC Inhibition and Colonocyte Metabolism

Butyrate (n-butyric acid; 4C SCFA; pKa 4.82; 0.1–1 mM faecal but 5–100 mM in the colonic lumen near mucosa; primary colonocyte energy substrate — ~70% of colonocyte ATP) is the most studied SCFA for epigenetic effects: butyrate inhibits class I/IIa HDAC (HDAC1/2/3/8; HDAC4/5/7/9; IC50 ~50–500 μM via butyrate binding to the Zn²&sup+;-coordinating catalytic site blocking substrate access) → H3K9Ac/H3K27Ac ↑ at FOXP3 (Treg induction; Treg ↑ in colon), HO-1 (Nrf2 target; HMOX1 promoter; butyrate alone or Nrf2-synergistic), and p21/CDKN1A (colonocyte growth arrest) promoters. Butyrate also activates Nrf2 directly (KEAP1 Cys273/Cys288 modification proposed by butyrate metabolite R-3-hydroxybutyrate); and inhibits NF-κB (butyrate → IκBα stabilisation via HDAC3 inhibition → NF-κB acetylation at p65 Lys310 by CBP/p300 not countered by deacetylase→paradoxically HDAC3-inhibited NF-κB is less transcriptionally active). MCT1 (SLC16A1) transports butyrate into colonocytes; MCT4 into portal blood.

Propionate and Acetate: GPR41/43 and Systemic Effects

Propionate (3C SCFA) and acetate (2C SCFA) signal via GPCRs: GPR41/FFAR3 (propionate > butyrate > acetate; Gi/Gβγ→ERK; enteroendocrine L-cells → PYY ↑, GLP-1 ↑ → satiety/insulin secretion); GPR43/FFAR2 (acetate > propionate; Gi + Gαq; colonocytes; adipocytes; neutrophils; GPR43→AMPK in adipocytes→FAO ↑; GPR43→GLP-1 in L-cells). Propionate reaches the liver via portal vein → hepatic gluconeogenesis inhibition (propionate → succinate → oxaloacetate; PEPCK/PC competition) and cholesterol synthesis suppression (propionate inhibits HMGCR at mevalonate pathway; ~10–20% LDL-C ↓). Acetate is the primary substrate for peripheral lipogenesis (ACLY; cytoplasmic; acetyl-CoA → malonyl-CoA path) but at physiological colonic concentrations primarily supports colonocyte energy metabolism.

Gut Barrier: Tight Junctions and Mucus

The intestinal epithelial barrier is maintained by tight junction (TJ) proteins: ZO-1 (TJP1; scaffolding; PDZ domains; binds claudins/occludin/JAM-A); claudin-1/2/3/4/5 (tetraspan; selective pores or tight seals; claudin-2 ↑ in IBD → leaky gut); occludin (Thr403/Ser490 phosphorylation by CK2 disrupts barrier; Tyr398/402 Src kinase phosphorylation → endocytosis); JAM-A (F11R; apical junctional complex); and adherens junctions E-cadherin/β-catenin. NF-κB drives claudin-2 transcription (κB site at −200 bp) and MMP-3 (TJ degradation); myosin light chain kinase (MLCK; EC 2.7.11.18; CaM-activated) phosphorylates MLC (myosin light chain) → actomyosin contraction → TJ opening. Butyrate maintains TJ: HDAC inhibition→H3K27Ac→ZO-1/occludin ↑; and inhibits MLCK transcription (NF-κB-dependent MLCK promoter).

Spirulina’s Mechanistic Actions

• Spirulan → selective microbiome enrichment: Spirulan fermentation increases Akkermansia muciniphila (mucin-degrading; Amuc_1100 TLR2 ligand; butyrate/propionate producer; gut barrier ↑) +30–50%; Bifidobacterium longum/adolescentis (acetate; folate producer) +20–40%; F. prausnitzii (butyrate; anti-inflammatory MAMP) +20–35% in mouse and human trials; Proteobacteria (LPS-producers) ↓ 20–35%.
• Butyrate ↑ → HDAC ↓ → Nrf2/HO-1/FOXP3 ↑: Faecal butyrate ↑ 20–35% (spirulina polysaccharide fermentation); colonic HDAC1/3 inhibition → H3K27Ac at HMOX1/FOXP3/CDKN1A promoters ↑; colonic HO-1 ↑ 20–30%; Treg (FOXP3&sup+;) in LP ↑ 20–30% → immune tolerance ↑; colonic NF-κB ↓ (HDAC3 inhibition → p65 Lys310 less deacetylated → transcriptional activity ↓ paradoxically).
• Propionate → GPR43 → AMPK/GLP-1: Propionate ↑→GPR43/FFAR2 L-cells → GLP-1 ↑ 10–20%; GPR43 adipocytes → AMPK Thr172 ↑→FAO ↑; portal propionate → hepatic gluconeogenesis ↓ 10–15% (PEPCK/PC competition).
• Gut barrier TJ maintenance: Butyrate→NF-κB↓→claudin-2 ↓; ZO-1/occludin ↑ 15–25%; MLCK transcription ↓ → MLC phosphorylation ↓ → TJ opening ↓; LPS absorption (from Proteobacteria ↓) ↓ → systemic LPS/TLR4 ↓ → NF-κB ↓ (systemic anti-inflammatory loop).
• PCB direct antimicrobial/modulatory effects: Phycocyanin and C-phycoerythrin selectively suppress pathogenic Clostridium difficile and E. coli in vitro while sparing Bifidobacterium/Lactobacillus (proposed via haem-like PCB moiety disrupting pathogen cytochromes; insufficient human data but consistent with microbiome shift data).

Clinical Correlates and Dosing

Human RCTs: 2–8 g/day spirulina for 8–16 weeks → faecal butyrate ↑ 20–35%; Akkermansia ↑ 30–50%; Bifidobacterium ↑ 20–40%; GLP-1 ↑ 10–20%; LPS ↓ 20–30% (endotoxaemia marker); IL-6 ↓ 20–40% consistent with gut barrier improvement. In IBD pilot studies (Crohn’s, UC), histological inflammation scores ↓ 20–30% (small n). Interactions: antibiotics — may disrupt spirulina prebiotic effects; separate use or supplement post-antibiotic course. Probiotic supplements + spirulina: complementary (spirulina as prebiotic substrate enriches supplemented strains); no adverse interactions.